Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer

<p>Summarized metrics for WES data</p>

Enregistré dans:

Détails bibliographiques
Auteur principal:	Emil Christensen (15054394) (author)
Autres auteurs:	Iver Nordentoft (15054397) (author), Karin Birkenkamp-Demtröder (15054400) (author), Sara K. Elbæk (15054403) (author), Sia V. Lindskrog (15054406) (author), Ann Taber (15054409) (author), Tine G. Andreasen (15054412) (author), Trine Strandgaard (15054415) (author), Michael Knudsen (15054418) (author), Philippe Lamy (15054421) (author), Mads Agerbæk (15054424) (author), Jørgen B. Jensen (15054427) (author), Lars Dyrskjøt (15054430) (author)
Publié:	2025
Sujets:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Methods and Technology Biomarkers Prognostic biomarkers Genitourinary Cancers Bladder cancer Liquid Biopsy Translational Research
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
par: Emil Christensen (15054394)
Publié: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
par: Ruiyun Zhang (17142498)
Publié: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
par: Giuseppe Basile (15051269)
Publié: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
par: Iris van 't Erve (15054503)
Publié: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
par: Lavanya Sivapalan (15314248)
Publié: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
par: Kala Visvanathan (14952973)
Publié: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
par: Ismael Fernández-Miranda (15051932)
Publié: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
par: Andrew A. Davis (15030032)
Publié: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
par: Cloud P. Paweletz (14960112)
Publié: (2025)

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
par: James R. Larkin (14936324)
Publié: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
par: James R. Larkin (14936324)
Publié: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
par: James R. Larkin (14936324)
Publié: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
par: James R. Larkin (14936324)
Publié: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
par: James R. Larkin (14936324)
Publié: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
par: James R. Larkin (14936324)
Publié: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
par: Morten Lapin (15056728)
Publié: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
par: Morten Lapin (15056728)
Publié: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
par: Morten Lapin (15056728)
Publié: (2025)

Table S1 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S2 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S3 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S4 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S5 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S6 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Table S7 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
par: Nina Rao (15321199)
Publié: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
par: Sofie H. Tolmeijer (15313251)
Publié: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
par: Sofie H. Tolmeijer (15313251)
Publié: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
par: Sofie H. Tolmeijer (15313251)
Publié: (2025)

Supplementary Table S4 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
par: Chaoyang Zhang (15051876)
Publié: (2025)

Supplementary Table S6 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
par: Chaoyang Zhang (15051876)
Publié: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
par: Nam Q. Bui (14958210)
Publié: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
par: Francesca Orzan (15055579)
Publié: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
par: Francesca Orzan (15055579)
Publié: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
par: Francesca Orzan (15055579)
Publié: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
par: Xiaojiang Duan (15439264)
Publié: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
par: Xiaojiang Duan (15439264)
Publié: (2025)

Cannot write session to /tmp/vufind_sessions/sess_snmfgi2cseqms0k30459bbdiu4